Rethinking ADT: AI Biomarkers in Intermediate-Risk Prostate Cancer
A recently published cost-effectiveness analysis has found that using the ArteraAI Prostate Test to guide androgen deprivatio [...]
Real-World Validation of an Imaging-Only AI Model in Localized Prostate Cancer – Xinglei Shen
Xinglei Shen presents a real-world validation of ArteraAI's multimodal risk model and a next-generation imaging-only version. [...]
Personalizing Prostate Cancer Care with the ArteraAI Prostate Test – Jason Hafron, MD
Artificial intelligence is transforming nearly every aspect of healthcare, but what does that actually mean for men with pros [...]
From Testing to Treatment: Implementing Genomics and AI Tools in Prostate Cancer Care – Elisabeth Heath
Elisabeth Heath discusses genomic and AI-based biomarker tools in prostate cancer. Dr. Heath describes ArteraAI as a useful a [...]
External Validation of a Post-RP Multimodal AI Prognostic Model
Prognostication after radical prostatectomy (RP) remains one of the most clinically demanding challenges in prostate cancer m [...]
ArteraAI Offers a New Approach to Breast Cancer Treatment Decision-Making
Matthew Kurian, MD, examines ArteraAI Breast, a newly FDA-cleared multimodal platform that combines pathology imaging and cli [...]
CHHiP Trial Evaluates a Multimodal AI Biomarker in Localized Prostate Cancer – Anna Wilkins
Anna Wilkins describes her validation of the Artera MMAI biomarker, drawing on over 2,000 biopsies from the 3,200-patient CHH [...]
CHHiP Trial Analysis: Prognostic, Risk Stratification Value of MMAI Model for Localized Prostate Cancer
Anna Wilkins, PhD, of Royal Marsden Hospital Institute of Cancer Research (UK), details an external validation of a digital p [...]
Study Investigates an AI-Powered Prognostic Test in Salvage Radiation Therapy Patients – Paul Nguyen
Paul Nguyen discusses the Artera AI prostate test for post-prostatectomy BCR. The test combines clinical factors with AI-anal [...]